Destiny Pharma welcomes the G20 Leaders´ Declaration on Combatting Antimicrobial Resistance (AMR) following their meeting in Germany. The G20 Leaders highlighted:
- The importance of fostering Research & Development, particularly for priority pathogens as identified by the WHO
- Called for the establishment of a new international Research & Development Collaboration Hub to maximise the impact of existing and new anti-microbial basic and clinical research initiatives, as well as product development
- Invited all interested countries and partners to join this new initiative
- The G20 Leaders will also, in collaboration with relevant experts including from the OECD and the WHO, further examine practical market incentive options
The full G20 Leaders’ Declaration can be found here.
Andrew Jack of the Financial Times today reports that Angela Merkel, (German chancellor & G20 President), has put health at the centre of today and tomorrow’s meeting of leading nations in Hamburg. High on their agenda will be attempts to tackle Infectious Diseases that present a growing health, economic and security threat across borders. The G20 meeting will look at how to respond to pandemics and there will also be a specific emphasis on one significant threat that is well understood but still neglected: ‘Anti Microbial Resistance (AMR)’.
Yesterday, DRIVE-AB, a joint undertaking between the EU and the European Pharmaceutical Industry Association) commented on their findings that are pertinent to G20 commitments, calling for the following incentives to drive forward antibacterial drug R&D to combat AMR:
- Pay between $750 million and $2 billion Market Entry Rewards to companies introducing new antibacterial drugs
- Global banking institutions to offer novel financial instruments to further support antibacterial R&D
- Top up currently available AMR ‘Push’ funding by $250 million pa
- Develop health technology assessment reimbursement rules which recognise the societal value of antibiotics
- Establish multinational coordination and collaboration
The speed and frequency of emergence of new Superbugs was underlined by the World Health Organization today after reporting on the discovery of totally untreatable Superbug strains of gonorrhoea and warning of their potential spread. Two studies on gonorrhoea published in the journal PLOS Medicine documented cases in Japan, France and Spain of patients with strains of gonorrhoea against which no known antibiotic is effective. The WHO estimates 78 million people a year get gonorrhoea.
The current edition of the South East Business magazine features an interview with Dr Bill Love, founder and Chief Scientific Officer of Destiny Pharma. The full article can be found here.